Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: 2 | Rare Historical Photos

Amgen To Offer Cholesterol Drug At 60% Discount As Trump Administration's Call To Lower Drug Prices

Amgen Inc. (NASDAQ:AMGN) on Monday launched AmgenNow, a new direct-to-patient program starting with Repatha (evolucumab).

Benzinga · Oct 6, 2025

The Saturday Spread: 3 Beaten-Down Stocks Making a Statistical Case for a Comeback

Here’s an innovative approach to deciphering which red-stained stocks are actually worth a look for bullish contrarians.

Barchart · Sep 27, 2025

Amgen Expands US Manufacturing Network Amid New Tariff Policy

Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) announced a $650 million expansion of its U.S. manufacturing network.

Benzinga · Sep 26, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

European Advisory Panel Recommends Two AstraZeneca Drugs For Approval

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc.'s (NASDAQ:AMGN) Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Benzinga · Sep 22, 2025

EMA Backs Amgen Drug For Rare Autoimmune Disorder

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended extending the therapeutic indication of Amgen Inc.’s (NASDAQ:AMGN) Uplizna (inebilizumab) to include the treatment of adult patients with active immunoglobulin G4-related disease (IgG4-RD).

Benzinga · Sep 19, 2025

Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis

Amgen Inc. (NASDAQ:AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) on Tuesday.

Benzinga · Sep 9, 2025

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug

On Wednesday, Amgen Inc. (NASDAQ:AMGN) and its partner Zai Lab (NASDAQ:ZLAB) said the final analysis of the Phase 3 FORTITUDE-101 trial evaluating bemarituzumab in combination with chemotherapy (mFOLFOX6) in first-line gastric cancer has been completed.

Benzinga · Sep 4, 2025

Read news from The Economist, FT, and more,
with one subscription

Is Amgen Stock Underperforming the S&P 500?

Analysts continue to favor Amgen stock, despite its relative underperformance to the broader S&P 500 Index.

Barchart · Sep 1, 2025

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up

BeOne Medicines Ltd. (NASDAQ:ONC) on Monday agreed to sell its royalty rights on the worldwide sales, excluding China, of Amgen Inc.’s (NASDAQ:AMGN) Imdelltra (tarlatamab-dlle) for up to $950 million to Royalty Pharma Inc. (NASDAQ:RPRX).

Benzinga · Aug 25, 2025

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday.

Benzinga · Aug 6, 2025

RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program

Three major pharmaceutical companies — Amgen Inc. (NASDAQ:AMGN), Eli Lilly and Co (NYSE:LLY), and UCB SA (OTC:UCBJY) (OTC:UCBJF) — are suing U.S. Secretary of Health and Human Services (HHS) Robert F. Kennedy Jr. over the way his department is handling a drug discount program.

Benzinga · Aug 6, 2025

Amgen Delivers Beat And Raise Quarter; Has Strong Late-Stage Pipeline

Amgen Inc‘s (NASDAQ:AMGN) second quarter results demonstrate ongoing development of its late-stage pipeline “to offset end-of-decade losses-of-exclusivity," according to Goldman Sachs.

Benzinga · Aug 6, 2025

Do Wall Street Analysts Like Amgen Stock?

Amgen has notably outpaced the broader market and the healthcare sector in 2025, and analysts remain cautiously optimistic about the stock’s prospects.

Barchart · Aug 4, 2025

Earnings Preview: What to Expect From Amgen’s Report

Amgen is set to release its second-quarter earnings next month, and analysts are projecting modest single-digit growth in profit.

Barchart · Jul 16, 2025

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Jun 23, 2025

Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update

Amgen Inc (NASDAQ:AMGN) shares are trading lower by 5.7% to $272.88 Monday afternoon after the company released full results from part one of its phase two study of MariTide, its investigational obesity treatment.

Barchart · Jun 9, 2025

How Is Amgen's Stock Performance Compared to Other Pharmaceuticals Stocks?

Amgen has underperformed the Pharmaceuticals industry over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart · May 5, 2025

Amgen Stock Outlook: Is Wall Street Bullish or Bearish?

Although Amgen has lagged behind the broader market over the past year, Wall Street analysts remain cautiously optimistic about the company’s long-term outlook.

Barchart · May 1, 2025

Stocks Soar Before the Open on Upbeat Microsoft and Meta Results, More Big Tech Earnings on Tap

June S&P 500 E-Mini futures (ESM25) are up +1.18%, and June Nasdaq 100 E-Mini futures (NQM25) are up +1.68% this morning as forecast-beating quarterly results from Microsoft and Meta boosted sentiment.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart · Apr 21, 2025

Amgen's Quarterly Earnings Preview: What You Need to Know

Amgen is scheduled to report its first-quarter results next month, and analysts expect a single-digit earnings growth.

Barchart · Mar 6, 2025

Is Bristol-Myers Stock Outperforming the Dow?

As Bristol-Myers has outperformed the Dow recently, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart · Mar 4, 2025

Amgen Stock: Is AMGN Outperforming the Healthcare Sector?

Amgen has outperformed the healthcare sector over the past year, and analysts are moderately optimistic about the stock’s prospects.

StockNews.com · Feb 25, 2025

3 Pharmaceutical Stocks Betting Big on Weight Loss Drugs

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, pharmaceutical giants like Eli Lilly and Company (LLY), Novo Nordisk (NVO), and Amgen (AMGN) are betting big on next-generation weight loss treatments to dominate this booming market. Keeping reading.

Barchart · Feb 12, 2025

Wall Street Predicts This Dividend Stock to Soar 31%: Should You Buy The Dip Now?

Amgen stock is an attractive buy on the dip for passive income-focused investors.

StockNews.com · Feb 10, 2025

3 Biotech Stocks Revolutionizing Healthcare

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and transformative partnerships. To capitalize on this trend, consider adding Amgen (AMGN), BioNTech (BNTX), and Gilead Sciences (GILD), which could boost your portfolio.

MarketBeat · Feb 5, 2025

Earnings Miss? Amgen’s Dividend Still a Bright Spot

AMGN stock is down over 1% despite beating revenue and earnings estimates; investors are selling the news on the company’s latest obesity drug and weak guidance

1 2 3 4 5

Coverage From

People

Donald Trump

216,861 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations